rLAS-uPA-eGP was fusogenic in uPAR expressing canine J3T and human U87 glioma cells (Figure 3), and the starting dose (dose cohort 1; Figure 1) of rLAS-uPA administered to dogs was derived from the median tissue culture infective dose (TCID50) obtained from J3T canine glioma cell line experiments. The gene discussed is PLAU; the disease is glioma.